Leveraging Innovation To Deliver Precision Medicines

Our Strategy

Our Strategy

Our strategy and business model

Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms

Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries

Fast track promising assets from discovery to clinical proof of concept

Advance programs into pivotal studies and commercialization through creative partnerships

Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise

Key differentiators

Speed & Efficiency
Agile business model with asset-based subsidiaries geared for speed, efficiency and creative partnerships to rapidly bring new cures to market

Leadership of experienced drug hunters to direct 50+ dedicated, highly skilled scientists from Jubilant Pharmova

World-class R&D Engine
Advanced R&D engine to discover and develop innovative, precision therapeutics

First-in-Class Programs and Strong IP Portfolio Including:
The only known dual epigenetic inhibitor of LSD1/HDAC6 for genetically-defined cancers First-in-class PAD4 inhibitor with potential in multiple auto-immune disorders

Leveraging innovation to deliver precision medicines in oncology and auto-immune diseases

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.